Related references
Note: Only part of the references are listed.
Article
Immunology
Yaki Saciuk et al.
Summary: A retrospective cohort study in Israel showed that a third dose of the BNT162b2 vaccine provides added protection against SARS-CoV-2 infection, especially for those vaccinated six months ago. The vaccine's effectiveness was found to be 92.9% in terms of prevention of infection, highlighting the importance of booster doses in maintaining immunity.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Sue Ann Costa Clemens et al.
Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.
Article
Infectious Diseases
Gang Zeng et al.
Summary: The study showed that a two-dose schedule of CoronaVac generated good immune response in adults, and a third dose given 8 months after the second dose effectively recalled specific immune responses to SARS-CoV-2, leading to a remarkable increase in antibody concentration. This indicates that the two-dose schedule provides good immune memory, and a primary third dose given 2 months after the second dose induced slightly higher antibody titres than the primary two doses.
LANCET INFECTIOUS DISEASES
(2022)
Article
Microbiology
Kuan-Ting Liu et al.
Summary: In this study, an enzyme-linked immunosorbent assay (ELISA) was developed to detect SARS-CoV-2-neutralizing antibodies in serum. The method accurately quantified neutralizing antibody titers and showed potential for assessing vaccine efficacy.
Article
Cell Biology
Yihao Liu et al.
Summary: SARS-CoV-2 inactivated vaccines have demonstrated significant efficacy in reducing severe illness and death. Despite a decline in humoral immunity over time, memory B and T cells remain detectable and can provide a quick recall response. A third booster dose enhances the immune response and improves the durability of protective immunity. Additionally, healthcare workers with low serological response to two doses still possess immune memory that can be quickly recalled by a third dose.
Editorial Material
Infectious Diseases
Feng Zhu et al.
Article
Infectious Diseases
Denis Saure et al.
Summary: The study in Chile found that individuals who received the CoronaVac vaccine had a lower IgG seropositivity compared to those who received the BNT162b2 vaccine. Over time, the IgG seropositivity for CoronaVac recipients declined, while those who received BNT162b2 maintained high levels of IgG positivity. Further monitoring of IgG levels will help in evaluating vaccine effectiveness and exploring potential adjustments to vaccination strategies in the future.
LANCET INFECTIOUS DISEASES
(2022)
Article
Immunology
Miguel Hueda-Zavaleta et al.
Summary: This prospective cohort study investigated the effects of a heterologous booster on humoral immune response in adult patients who were initially vaccinated with the BBIBP-CorV vaccine. The study found that the antibody levels were higher in previously infected individuals after immunization, while in non-infected individuals, the increase in antibody levels was more pronounced after immunization.
Article
Infectious Diseases
Juan C. Gomez de la Torre et al.
Summary: Insufficient data have been reported about the effect of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) on the humoral response through time in healthcare workers (HCW). This retrospective cohort study compared the antibody-mediated response provoked by BBIBP-CorV between HCW previously infected with SARS-CoV-2 (PI) and not previously infected (NPI). The study found that there was a progressive decrease in antibody levels over time in both groups, with the NPI group showing a higher decrease.
TROPICAL MEDICINE AND INFECTIOUS DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Massimo Pieri et al.
Summary: The study found a good agreement between commercial surrogate Virus Neutralization Tests (sVNTs) and the conventional virus neutralization test (VNT). Despite VNT remaining the gold standard, sVNTs may be a valuable tool for screening wider populations.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2022)
Article
Infectious Diseases
Shengli Xia et al.
Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Alasdair P S Munro et al.
Article
Medicine, General & Internal
Ronen Arbel et al.
Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Rima Moghnieh et al.
Summary: A study conducted in Lebanon found that administering a BNT162b2 booster dose to COVID-19-naive individuals who had received two doses of the BBIBP-CorV vaccine was safe and resulted in significantly higher anti-spike IgG levels compared to homologous BNT162b2 immunization.
Article
Immunology
Felipe Melo-Gonzalez et al.
Summary: Vaccination with CoronaVac promotes the secretion of antibodies capable of blocking SARS-CoV-2 variants of concern and partially neutralizing SARS-CoV-2 infection. Additionally, it stimulates cellular responses against all variants of concern.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Geriatrics & Gerontology
Istvan Valyi-Nagy et al.
Summary: This study compared the humoral and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines against the SARS-CoV-2 virus, revealing significant quantitative and qualitative differences between the two. BBIBP-CorV vaccine induced high levels of antibody responses in healthy individuals, while BNT162b2 showed slightly higher T cell responses.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Biochemistry & Molecular Biology
Joseph E. Ebinger et al.
Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Article
Medicine, General & Internal
Maren Werner et al.
Summary: Serological testing is important for detecting previous infection and monitoring immunity. This study evaluated 16 ELISA/ECLIA and 16 LFA tests using 161 sera samples. Specificities of ELISA/ECLIA tests were acceptable, but sensitivities were lower; LFAs were less accurate than ELISAs. A combination of nucleocapsid and spike protein-based tests is recommended for maximal sensitivity.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Immunology
Jang Hyun Park et al.
Summary: The development of COVID-19 vaccines includes various types such as subunit vaccines, inactivated vaccines, and nucleic acid vaccines, but currently only intramuscular vaccination is available. Research suggests that mucosal vaccination may enhance local immune responses, but the lack of understanding of mucosal immunity combined with the urgent need for a COVID-19 vaccine has resulted in the limited delivery options available at present.
Article
Cell Biology
Yunlong Cao et al.
Summary: The study found that the diversity of anti-RBD NAbs plays a major role in neutralization against SARS-CoV-2 variants, especially 501Y.V2, with E484K being the dominant cause of neutralization reduction. Specific antibodies respond differently to mutations in RBD variants, with lower diversity observed in NTD antibodies. RBD-subunit vaccinees exhibit higher tolerance to neutralization against variants, while extending the interval between doses of ZF2001 enhances neutralizing activity and tolerance to variants.
News Item
Multidisciplinary Sciences
Smriti Mallapaty
Article
Immunology
Olivera Lijeskic et al.
Summary: Real-life data on vaccine performance against SARS-CoV-2 is limited. Antibody levels were higher in individuals who received BNT-162b2 and Gam-COVID-Vac compared to those who received BBIBP-CorV, with BNT-162b2 maintaining high levels even 3 months post-vaccination.
Article
Chemistry, Multidisciplinary
Qingyu Zhao et al.
Summary: Peptide epitopes from the spike protein of SARS-CoV-2 were synthesized and linked with CRM197 to immunize mice, leading to high titers of IgG antibodies that effectively neutralized SARS-CoV-2 pseudovirus. This study suggests that the identified epitopes are protective and the conjugates are promising for the development of an anti-SARS-CoV-2 vaccine.
CHEMICAL COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Qiang Gao et al.
